{"nctId":"NCT00984126","briefTitle":"Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015","startDateStruct":{"date":"2009-10-26","type":"ACTUAL"},"conditions":["Congenital Bleeding Disorder","Haemophilia A"],"count":214,"armGroups":[{"label":"Turoctocog alfa","type":"EXPERIMENTAL","interventionNames":["Drug: turoctocog alfa"]}],"interventions":[{"name":"turoctocog alfa","otherNames":[]},{"name":"turoctocog alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed Consent obtained before any trial-related activities\n* Completion of trial NN7008-3543 or paediatric trial NN7008-3545 or Japanese trial NN7008-3600 or pharmacokinetic trial NN7008-3893 or NN7008-4015\n\nExclusion Criteria:\n\n* Previous participation in the current trial (defined as withdrawal) or withdrawn subjects from NN7008-3522, NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 or NN7008-4015 after administration of trial product","healthyVolunteers":false,"sex":"MALE","minimumAge":"6 Months","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of Development of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)/mL)","description":"The frequency of inhibitors was calculated as number of patients with inhibitors during the trial divided by number of patients in the trial. This endpoint was measured during the trial.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events and Serious Adverse Events","description":"The number of adverse events and serious adverse events reported during the main trial and the on-demand sub-trial (during 90 months).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"204","spread":null},{"groupId":"OG002","value":"240","spread":null},{"groupId":"OG003","value":"636","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualised Bleeding Rate Reported During the Prevention Period (Only Applicable for Subjects in the Preventive Regimen)","description":"The number of bleeding episodes per year reported during the prevention period (during 90 months).","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"1.57","spread":null},{"groupId":"OG002","value":"1.57","spread":null},{"groupId":"OG003","value":"1.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemostatic Response to Turoctocog Alfa (None, Moderate, Good or Excellent) in Treatment of Bleeds.","description":"Haemostatic response to turoctocog alfa (none, moderate, good or excellent) in treatment of bleeds using a four-point response scale: none, moderate, good or excellent. The evaluation was done by patient, caregiver and/or investigator based on experience as follows: 1. Excellent: Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single infusion 2. Good: Definite pain relief and/or improvement in signs of bleeding within approximately 8 hours after an infusion, but possibly requiring more than 1 infusion for complete resolution. 3. Moderate: Probable or slight beneficial effect within approximately 8 hours after the first infusion; usually requiring more than 1 infusion. 4. None: No improvement, or worsening of symptoms. This endpoint is measured during the preventive and on-demand sub-trial (during 90 months).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"189","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"565","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"150","spread":null},{"groupId":"OG006","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"103","spread":null},{"groupId":"OG003","value":"382","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"22","spread":null},{"groupId":"OG006","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"91","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":27},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Arthralgia","Cough"]}}}